A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern Medicine meta-analysis published in JAMA Oncology.
Investigators have discovered novel intercellular “crosstalk” between epidermal keratinocytes and melanoma cells that promotes cancer growth and metastasis, which could also serve as biomarkers for early cancer detection, according to a recent Northwestern Medicine study.
Northwestern Medicine investigators have identified new molecular details regarding how white blood cells move across the walls of microvessels during inflammation, revealing new potential molecular targets for treating the condition, according to a new study published in the journal Immunity.
Northwestern Medicine investigators have discovered a novel mechanism that regulates neutrophil recruitment into tissue during inflammation, which could be targeted to treat different inflammatory diseases and conditions, according to a recent study published in the Journal of Clinical Investigation.
Northwestern scientists discovered how to soften hair follicle stem cells to enable them to grow hair again, according to a study published in Proceedings of the National Academy of Sciences.
Investigators have discovered that a specific complex drives cell proliferation in mutated myeloproliferative neoplasms, suggesting this complex could serve as an ideal therapeutic target, according to a recent Northwestern medicine study.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
Northwestern Medicine investigators have identified novel intracellular mechanisms that could serve as future therapeutic targets for inflammatory skin diseases.
Proteins gain new interactions that are potentially oncogenic and could drive cancer development and growth, according to a recent study.
Daniel Brat, MD, PhD, has been heavily involved in the process of moving molecular genetic biomarkers for glioma from the bench to the beside.